about
Cellular and molecular biology of small cell lung cancer: an overviewIntegrating the molecular background of targeted therapy and immunotherapy in lung cancer: a way to explore the impact of mutational landscape on tumor immunogenicityPlatelets and their role in cancer evolution and immune systemMelanoma: oncogenic drivers and the immune systemDeciphering Crosstalk Circuits in Non-small Cell Lung Cancers with an Increasing Interval Length of Low Dose CT ScreeningDifferential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers.Moving towards a customized approach for drug development: lessons from clinical trials with immune checkpoint inhibitors in lung cancerClinical results of randomized trials and 'real-world' data exploring the impact of Bevacizumab for breast cancer: opportunities for clinical practice and perspectives for research.Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC.Prognostic impact of alternative splicing-derived hMENA isoforms in resected, node-negative, non-small-cell lung cancer.Progression-free survival as primary endpoint in randomized clinical trials of targeted agents for advanced renal cell carcinoma. Correlation with overall survival, benchmarking and power analysis.Molecular heterogeneity assessment by next-generation sequencing and response to gefitinib of EGFR mutant advanced lung adenocarcinoma.BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancerClinico-pathological nomogram for predicting BRAF mutational status of metastatic colorectal cancer.Comprehensive molecular portrait using next generation sequencing of resected intestinal-type gastric cancer patients dichotomized according to prognosis.Predictive and Prognostic Role of Tumor-Infiltrating Lymphocytes for Early Breast Cancer According to Disease Subtypes: Sensitivity Analysis of Randomized Trials in Adjuvant and Neoadjuvant SettingSubpopulation Treatment Effect Pattern Plot (STEPP) analysis of Ki67 assay according to histology: prognostic relevance for resected early stage 'pure' and 'mixed' lobular breast cancer.ALK gene copy number gains in non-small-cell lung cancer: prognostic impact and clinico-pathological correlations.MET exon 14 juxtamembrane splicing mutations: clinical and therapeutical perspectives for cancer therapy.PROFILing non-small-cell lung cancer patients for treatment with crizotinib according to anaplastic lymphoma kinase abnormalities: translating science into medicine.Advances towards the design and development of personalized non-small-cell lung cancer drug therapy.Anti-angiogenic drugs and biomarkers in non-small-cell lung cancer: a 'hard days night'.Predictors of outcome for patients with lung adenocarcinoma carrying the epidermal growth factor receptor mutation receiving 1st-line tyrosine kinase inhibitors: Sensitivity and meta-regression analysis of randomized trials.Targeting the epidermal growth factor receptor in solid tumors: focus on safety.Immune checkpoint inhibitors for non-small-cell lung cancer: does that represent a 'new frontier'?An overview of angiogenesis inhibitors in Phase II studies for non-small-cell lung cancer.The coming of ramucirumab in the landscape of anti-angiogenic drugs: potential clinical and translational perspectives.Outcomes of First-Generation EGFR-TKIs Against Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Post Hoc Analysis of the BE-POSITIVE Study.Prognostic impact of proliferation for resected early stage 'pure' invasive lobular breast cancer: Cut-off analysis of Ki67 according to histology and clinical validation.Tubulin inhibitors in non-small cell lung cancer: looking back and forward.Current and developing therapies for the treatment of non-small cell lung cancer with ALK abnormalities: update and perspectives for clinical practice.Prognostic model for advanced breast carcinoma with luminal subtype and impact of hormonal maintenance: Implications for post-progression and conditional survival.Addressing the expected survival benefit for clinical trial design in metastatic castration-resistant prostate cancer: Sensitivity analysis of randomized trials.Risk Stratification Model for Resected Squamous-Cell Lung Cancer Patients According to Clinical and Pathological Factors.Predictive role of erythrocyte macrocytosis during treatment with pemetrexed in advanced non-small cell lung cancer patients.Lung neuroendocrine tumours: deep sequencing of the four World Health Organization histotypes reveals chromatin-remodelling genes as major players and a prognostic role for TERT, RB1, MEN1 and KMT2D.Tracking MET de-addiction in lung cancer: A road towards the oncogenic target.Tracking occult pN2 disease after mediastinal dissection in early stage lung cancer.Prognostic Model for Resected Squamous-Cell Lung Cancer: External Multicenter Validation and Propensity Score Analysis exploring the Impact of Adjuvant and Neoadjuvant Treatment.Effect of Contract Research Organization Bureaucracy in Clinical Trial Management: A Model From Lung Cancer.
P50
Q26767029-7C469FF9-589E-47B5-9AAB-C4CABB586514Q26769744-5F8F7EE9-6885-4525-BC6B-1668D2931E51Q26769754-006D0E62-7E08-47D8-A676-385C5F844E41Q26775598-115BE66B-8451-4A07-B78C-E4D11AF94FE5Q26783155-4958902B-59A3-496E-AC2F-46A0DAA3D2D2Q27853176-722D8072-7FB6-44D3-AD73-5868C253D2DFQ28072004-AB4F5236-82D6-454A-95A5-2CAC15F8B947Q31157714-9E6CC7BD-3C9C-4476-98AC-3C9FD442D277Q33614314-4BC3F854-D9CB-4078-8E6E-3472CB49AE10Q34957141-DEFA3BE9-A8A1-4BB2-9A44-0C4854C29F80Q35241042-53B97382-83CF-4173-A2EB-10886B08A967Q35828688-69F7747C-6A9F-4449-BFE8-1BD62CB0CFFFQ36350128-D0ABBB41-AF17-46F9-B438-274057EAB42FQ36472959-07CCAC9B-F91A-4B11-A44A-9CF11FB5FA82Q36670779-40810A70-756C-4733-A5BD-8929BC5C7435Q36673469-CA2D74A1-56E3-4465-AB1B-70A2285B649AQ36715181-AE53A414-F165-4A2C-BDB4-772C79F001B6Q37209474-D5BB4C7E-3B39-4A46-818B-9811E9632C33Q37597858-6397C39F-1300-4A59-8336-350A1845B744Q38087648-B11D33FD-643C-43FA-B017-92F74B660B7FQ38148583-ED069AEC-0487-4729-9BD1-63B10D938FB7Q38153830-18ADE316-F71B-4049-B3E7-DD6A50FDB8B1Q38170834-DF79A101-5D56-4229-BAEF-AF0870272AF6Q38200654-9F6A9211-4B28-4B4B-AABE-552172AB9E84Q38266331-9FE0D177-F05C-4027-BAC0-4C88009FB9EAQ38525073-4F1150D2-11A3-4579-AD6F-C1C8A274E92BQ38550459-DEA984F1-B21C-4110-9194-9CD67244ACD6Q38711537-67B7E576-9B97-4B13-BEED-9F005A62CF62Q38719132-5CD14326-6E36-4785-94B2-51E3C668E33EQ38742506-F6500916-4762-4221-819A-07A4A9C997E0Q38816700-51127529-B6B2-4CDA-9B4E-74B931AE5A9EQ39618636-518A481E-47C8-4068-9BC1-3903B0994A2BQ40240894-0057CE37-2772-4326-96B2-BE3EECFF0094Q40709010-9D836177-B84B-48AC-915B-EBAFAE0CE5EEQ41078090-070B8DCA-4A42-4C57-B243-ED0A6BCED790Q41981114-EB1F72FD-2DDC-4753-B16C-6E2B82FBEA4AQ45066071-4A022F44-0DBA-43D9-9072-4706DAB14F47Q47119613-7D29900D-271C-4A5F-8716-27B345D51942Q47264723-F57C59C6-C0BA-4AC5-AF15-16D4695690B4Q47446534-20A274E4-B880-43A0-B4C5-7FB268650D13
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Sara Pilotto
@ast
Sara Pilotto
@en
Sara Pilotto
@es
Sara Pilotto
@nl
type
label
Sara Pilotto
@ast
Sara Pilotto
@en
Sara Pilotto
@es
Sara Pilotto
@nl
prefLabel
Sara Pilotto
@ast
Sara Pilotto
@en
Sara Pilotto
@es
Sara Pilotto
@nl
P106
P1153
54879746600
P21
P31
P496
0000-0003-2229-4874